HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings

Palisade Bio, Inc. (NASDAQ:PALI) – Stock analysts at HC Wainwright cut their Q3 2026 EPS estimates for Palisade Bio in a research note issued to investors on Tuesday, August 11th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.05) per share for the quarter, down from their prior forecast of ($0.04). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for Palisade Bio’s FY2026 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.22) EPS.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $0.50 million.

Several other research analysts have also commented on PALI. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings cut Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Finally, Oppenheimer assumed coverage on shares of Palisade Bio in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $8.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $9.00.

Palisade Bio Price Performance

Shares of PALI stock opened at $1.96 on Thursday. The company has a 50-day moving average of $1.94 and a two-hundred day moving average of $1.91. The firm has a market cap of $341.57 million, a PE ratio of -1.94 and a beta of 1.52. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.86.

Institutional Investors Weigh In On Palisade Bio

Large investors have recently modified their holdings of the company. Cetera Investment Advisers acquired a new position in shares of Palisade Bio in the 4th quarter valued at $25,000. Schonfeld Strategic Advisors LLC purchased a new position in Palisade Bio during the 4th quarter worth $26,000. Virtu Financial LLC purchased a new position in Palisade Bio during the 4th quarter worth $28,000. CTC Alternative Strategies Ltd. acquired a new position in Palisade Bio in the first quarter valued at $31,000. Finally, Atom Investors LP acquired a new position in Palisade Bio in the fourth quarter valued at $33,000. 11.79% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Robert Jr. Baltera bought 30,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were acquired at an average price of $2.03 per share, for a total transaction of $60,900.00. Following the completion of the transaction, the director owned 416,904 shares of the company’s stock, valued at approximately $846,315.12. This trade represents a 7.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John David Finley sold 146,798 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total value of $303,871.86. Following the completion of the sale, the chief executive officer directly owned 217,555 shares of the company’s stock, valued at approximately $450,338.85. This trade represents a 40.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have bought 125,000 shares of company stock valued at $250,100. 0.07% of the stock is currently owned by insiders.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.